OXiGENE licenses Angiogene's know-how to support carcinoid syndrome PhII work
This article was originally published in Scrip
Executive Summary
OXiGENE, a clinical-stage company based in South San Francisco, has gained worldwide rights to the intellectual property and know-how relating to Oxford, UK-based Angiogene Pharmaceuticals' vascular disrupting agent programme for neuroendocrine cancers, focused mainly on carcinoid syndrome.